---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076058"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-06-22T11:00:29+00:00"
generated_at: "2026-06-22T11:05:45.381180+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma to resubmit TXM data package to UK MHRA in Q3 2026 for Phase 2a influenza challenge study

## Summary
- Resubmission of updated toxicology data package to MHRA expected in Q3 2026.
- Formal MHRA response anticipated within 30 days after resubmission.
- Data package intended to enable Phase 2a human influenza Challenge study of tivoxavir marboxil (TXM).
- TXM targets seasonal influenza prophylaxis; preclinical data showed broad in vitro efficacy.

## SEC filing metadata
- accession: 0001104659-26-076058
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-06-22T11:00:29+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926076058/0001104659-26-076058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926076058/tm2618195d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076058
- JSON: https://secwatch.observer/filing/0001104659-26-076058.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.